Categorical variables will be presented with numbers and, if meaningful, percentages. Continuous variables will be presented by n, mean, median, standard deviation and range (min and max) as appropriate. Presentations will be by each dose cohort. Safety Evaluable Population : All patients who received at least 1 dose of the study treatment . Efficacy Evaluable Population : All patients with pre -treatment measurable disease by RECIST 1.11, who had at least one radiological assessment after pre -treatment or discontinued study treatment early due to disease progression. Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 13 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page ABBREVIATIONS Abbreviation Definition AE Adverse Event ALT Alanine Transaminase APC Antigen Presenting Cell AST Aspartate Transaminase BUN Blood Urea Nitrogen CFR Code of Federal Regulations CR Complete Response CRF Case Report Forms CRO Contract Research Organization CRS Cytokine Release Syndrome CT Computed Tomography CTA Cancer Testis Antigen CTCAE Common Terminology Criteria for Adverse Events dL Deciliter DLT Dose Limiting Toxicity DMSO Dimethyl Sulfoxide EC Ethics Committee ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group ELISPOT Enzyme -Linked Immunosorbent Spot FDA Food and Drug Administration fg Femtogram GCP Good Clinical Practice GITR Glucocorticoid -Induced TNFR -Related Protein GLP Good Laboratory Practice gzB Granzyme B HIV Human Immunodeficiency Virus HLA Human Leukocyte Antigen hr Hour HSA Human Serum Albumin ICF Informed Consent Form ICH International Council for Harmonization ICOS Inducible T -Cell Costimulator IEC Independent Ethics Committee IFN-α Interferon -Alpha IHC Immunohistochemistry IL Interleukin IMP Investigational Medicinal Product IND Investigational New Drug (Application) IP Investigational Product irAE Immune Related Adverse Events IRB Institutional Review Board kg Kilogram Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 14 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page LD Longest Diameter LDH Lactate Dehydrogenase LVEF Left Ventricular Ejection Fraction MABEL Minimum Anticipated Biological Effect Level max Maximum MedDRA Medical Dictionary for Regulatory Activities mIHC Multiplex Immunohistochemistry min Minimum mL Milliliter MRI Magnetic Resonance Imaging MTD Maximum Tolerated Dose N/A Not Applicable NCI National Cancer Institute NE Inevaluable ng Nanogram NK Natural Killer Cells NOAEL No Observed Adverse Effect Level NOEL No Observed Effect Level NSCLC Mon -Small Cell Lung Cancer ºC Degree Celsius OS Overall Survival PBMC Peripheral Blood Mononuclear Cell PD Progressive Disease PET Positron Emission Tomography PFS Progression -Free Survival PR Partial Response RANK Receptor Activator of Nuclear Factor Kappa -Β RECIST Response Evaluation Criteria in Solid Tumors Version 1.1 RNA Ribonucleic Acid RP2D Recommended Phase 2 Dose RSI Reference Safety Information SAE Serious Adverse Event SARs Serious Adverse Reactions SD Stable Disease SGOT Serum Glutamic -Oxaloacetic Transaminase SGPT Serum Glutamic -Pyruvic Transaminase SOC Standard of Care SRC Safety Review Committee TBD To Be Decided TEAE Treatment Emergent Adverse Events TIL Tumor -Infiltrating Lymphocytes TLR Toll-Like Receptor TNF Tumor Necrosis Factor TNFRSF25 Tumor Necrosis Factor Receptor Superfamily Member 25. Tregs Regulatory T Cells TSH Thyroid -Stimulating Hormone Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 15 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page ULN Upper Limit of Normal US Ultrasound WBC White Blood Cell μg Microgram Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 16 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page 1.0 GENERAL INFORMATION 1.1 Protocol Number and Title of the Study Protocol No. : HS130 -001 Protocol Title: A Phase I, first -in-human, dose-escalation study to evaluate the safety and immunologic response after administration of HS -130 in combination with HS -110 (viagenpumatucel -L) in patients with solid tumors refractory to standard care 1.2 Sponsor Heat Biologics 627 Davis Drive, Suite 400 Morrisville , NC 27560 (919) 240-7133 1.3 Medical Monitor Vance Y. Sohn MD (253) 722-3144 vsohn@cancerinsight.com 1.4 Signature Authorization Heat Biologics will sign the protocol. 1.5 Investigator and Institution Rachel E.